Case Report: Severe rash/desquamation induced by sorafenib in an uHCC patient and its clinical management
Background: Sorafenib-related dermatological toxicity is a well-known adverse reaction that can severely affect therapeutic outcomes. Rash/desquamation with its variable manifestations is one of the common clinical presentations. Currently, no standard continuum of care for sorafenib-related rash/de...
Saved in:
Main Authors: | Yan Lin (Author), Ping-Yu Liu (Author) |
---|---|
Format: | Book |
Published: |
Frontiers Media S.A.,
2022-09-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Erythematous desquamating rash after initiation of chemotherapy
by: Jack Newcomer, BA, et al.
Published: (2023) -
Desquamative erythematous rash in a young woman
by: Delwyn Zhi Jie Lim, MRCP (UK), et al.
Published: (2023) -
Mechanism of sorafenib resistance associated with ferroptosis in HCC
by: Lingling Guo, et al.
Published: (2023) -
A 78-Year-Old Female with a Diffuse Pruritic Rash and Palmoplantar Desquamation
by: Gabriel E. Molina, et al.
Published: (2020) -
TKI or TKI combined with PD-1 inhibitors as second-line treatment for HCC patients after sorafenib failure
by: Jin Lei, et al.
Published: (2022)